Current Size: 100%

Meetings 2017

KickOff Meeting - the Vetmeduni Vienna Joins as a New Partner in the Ludwig Boltzmann Cluster Oncology (LBC ONC)

Date:  23rd August 2017

Venue:  University of Veterinary Medicine Vienna, Vienna, Austria

The LBC ONC celebrated a recently signed partnership contract between the LBG and the Vetmeduni Vienna by organizing a KickOff Meeting on August 23rd, 2017.

After an introduction by the rector of the Vetmeduni Vienna, Petra Winter and the area manager of the LBG, Peter Mayrhofer, the scientists involved in the partnership have presented their research projects.

The LBC ONC and the Vetmeduni Vienna have a long-standing partnership that goes back to the establishment of the LBC ONC in 2008. In 2017, this partnership was formalized by establishing a formal partnership agreement between the LBG and the Vetmeduni Vienna.

Research projects with the Vetmeduni Vienna focus on two major topics: comparative oncology and in vivo models.

Comparative oncology has the aim to improve cancer treatment of human- and animal patients by translating knowledge from one model to another. Fast translation of findings can promote rapid development of human anti-neoplastic drugs and enable veterinarians to treat their patients better by parallel development of drugs for the veterinary sector.

The Vetmeduni Vienna provides the LBC ONC with state-of-the-art expertise in the field of in vivo models, which is necessary for drug development and drug testing. The experience and knowledge of the Institute of Laboratory Animal Science is essential for the validation of newly found leukemic stem cell (LSC) markers and for testing the potential for elimination of LSC of newly developed drugs.


Workshop: Normal and Neoplastic Erythropoiesis: From Gene Regulation to Targeted Treatment Concepts

Date:  28th to 29th April 2017

Venue:  Medical University of Vienna, Vienna, Austria

From April 28th to 29th 2017 the working conference on erythroid disorders was held at the Medical University of Vienna. Important aspects in normal and neoplastic erythropoiesis regarding gene regulation and targeted treatment concepts were presented and discussed by leading experts in the field of hematology.

The first day of the workshop started with the welcome talk and introduction of Prof. Dr. Peter Valent who organized this notable occasion. During the first day, invited speakers from Germany, France, Switzerland and Austria presented important and interesting topics ranging from regulation and molecular mechanism of normal and neoplastic erythropoiesis, histologic and immunophenotypic evaluation of red cell production, pathogenesis, basic concepts and novel therapy approaches of anemias.

The second day was the closed part of the working conference where intensive talks and discussions were held from the international experts.The second part of this workshop focused especially on indication and standards of treatment in various forms of anemias. After the summary and closing remarks the faculty members were invited for dinner at a typical viennese restaurant in the 9th district of Vienna.

As a result of the workshop, the faculty members wrote a publication that summarizes new diagnsotics and prognostic markers, the WHO classification, and an novel drugs and treatment options for vaious indications, such as myelodysplastic syndroms (MDS) and other neoplasms (Haematologica October 2018 103: 1593-1603; doi:10.3324/haematol.2018.192518).


Comparative Oncology Mast Cell Meeting

Date:  24th to 25th March 2017

Venue:  University of Veterinary Medicine and Hotel Melia, DC Tower Vienna, Vienna, Austria

On May 24, 2017 the Comparative Oncology Meeting on Mast Cells and Mast Cell Neoplasms took place at the University of Veterinary Medicine of Vienna. The meeting entitled Mast Cell Neoplasms in Dogs and Men: From Gene Regulation to Targeted Treatment Concepts was organized by Peter Valent, Emir Hadzijusufovic and Michael Willmann.

Experts from Europe came together and presented their data on models for mast cell research, mutation analysis and treatment options for human and canine mast cell neoplasms. The canine patient is used as a model for human patients suffering from mast cell neoplasms, but also dogs can benefit from the knowledge and development of human cancer therapies. The main aim of this meeting was to improve oncological therapy in mast cell neoplasms of both humans and dogs.

On May 25, 2017 the closed session of the meeting was located at Meliá Vienna Hotel in the 22nd district of Vienna and focused especially on diagnosis and treatment for canine mast cell tumor. Topics ranged from diagnostic standards, value of KIT mutations in diagnosis and treatment stratification, symptomatic therapy in order to target mast cell mediators, current standards of therapy, and future standards. In order to summarize the meeting, the faculty members wrote a paper on comparative oncology in human and canine mast cell neoplasms (Willmann M et al., Vet Comp Oncol. 2018). In this paper, they review the current status of comparative oncology approaches in human and canine mast cell neoplasms.